Ces publications scientifiques et présentations sont proposées à des fins de formation uniquement. Elles peuvent mentionner ou discuter des produits de DBV Technologies en cours de développement, et qui ne sont approuvés pour commercialisation par aucune autorité règlementaire ou de santé dans aucun pays du monde.

• Remington BC, Campbell DE, et al. Post hoc analysis of epicutaneous immunotherapy for peanut allergy phase 3 results: Relevance for exposure through restaurant meals. Annals of Allergy, Asthma & Immunology. 2021. Feb126(2):208-209. doi: 10.1016/j.anai.2020.11.015.
• Brown-Whitehorn TF, de Blay F, et al. Sustained Unresponsiveness to Peanut After Long-term Peanut Epicutaneous Immunotherapy. The Journal of Allergy and Clinical Immunology: In Practice. 2021. Jan;9(1):524-526. doi: 10.1016/j.jaip.2020.08.017.
• DunnGalvin A, Fleischer DM, et al. Improvements in Quality of Life in Children Following Epicutaneous Immunotherapy (EPIT) for Peanut Allergy in the PEPITES and PEOPLE Studies. The Journal of Allergy and Clinical Immunology: In Practice. 2021. Jan;9(1):216-224.e1. doi: 10.1016/j.jaip.2020.08.015.
• Fleischer DM, Shreffler WG, et al. Long-Term, Open-Label Extension Study of the Efficacy and Safety of Epicutaneous Immunotherapy For Peanut Allergy in Children: PEOPLE 3-Year Results. The Journal of Allergy and Clinical Immunology. 2020. doi:10.1016/j.jaci.2020.06.028.
• Fleischer DM, Chinthrajah S, et al. An Evaluation of Factors Influencing Response to Epicutaneous Immunotherapy For Peanut Allergy in the PEPITES Trial. Allergy & Asthma Proceedings. 2020;41:1-10. doi:10.2500/aap.2020.41.200047. PMID: 32539908.
• Fleischer DM, Spergel JM, et al. Evaluation of Daily Patch Application Duration For Epicutaneous Immunotherapy For Peanut Allergy. Allergy & Asthma Proceedings. 2020;41:278-284. doi:10.2500/aap.2020.41.200045. PMID: 32517847.
• Greenhawt M, Kim EH, et al. Improvements in Eliciting Dose Across Baseline Sensitivities Following 12 Months of Epicutaneous Immunotherapy (EPIT) in Peanut-Allergic Children Aged 4 to 11 Years. The Journal of Allergy and Clinical Immunology: In Practice. 2020;S2213-2198(20)30526-2. doi:10.1016/j.jaip.2020.05.030. PMID: 32502548.
• Remington BC, Krone T, et al. Estimated Risk Reduction to Packaged Food Reactions by Epicutaneous Immunotherapy (EPIT) For Peanut Allergy. Annals of Allergy, Asthma & Immunology. 2019;123(5):488‐493.e2. doi:10.1016/j.anai.2019.08.007. PMID: 31442495.
• Fleischer DM, Greenhawt M, et al. Effect of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Ingestion Among Children With Peanut Allergy: The PEPITES Randomized Clinical Trial. JAMA. 2019;321:946-955. doi:10.1001/jama.2019.1113. PMID: 30794314.
• Sampson HA, Shreffler WG, et al. Effect of Varying Doses of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Exposure Among Patients With Peanut Sensitivity: A Randomized Clinical Trial. JAMA. 2017;318:1798-1809. doi:10.1001/jama.2017.16591. PMID: 29136445.

Ces résumés ont été approuvés pour présentation à un congrès médical et n’ont pas été soumis à une revue complète par des pairs.

Poster Presentations:

• Reduction in severity following 12 months of epicutaneous immunotherapy for peanut allergy (Abstract 342)
• Modulation of mast cells by epicutaneous immunotherapy (EPIT) to cashew allergy (Abstract L15)

Oral Presentations:

• Specific Peanut Epitopes as a Biomarker for Desensitization During Epicutaneous Immunotherapy (Abstract 7202)

Poster Presentations:

• An Evaluation of Factors Influencing Response to Epicutaneous Immunotherapy for Peanut Allergy in the PEPITES Trial (Abstract P301)
• Evaluation of Daily Patch Application Duration for Epicutaneous Immunotherapy for Peanut Allergy (Abstract P300)
• Patient Experiences with Epicutaneous Immunotherapy for Peanut Allergy in OLFUS-VIPES & REALISE Trials: Qualitative Studies (Abstract P307)

Oral Presentations:

• Efficacy and Safety of Epicutaneous Immunotherapy (EPIT) for Peanut Allergy in Subjects With and Without Concomitant Food Allergies (Abstract 1362)
• Late Breaker: Differences in Epitome Response in Peanut-Allergic Subjects Treated with Different Immunotherapy Preparations (Abstract 1776)
• Late Breaker: Epicutaneous Immunotherapy in Murine Model Modulates Humoral Immunity Through Regulation of IL-13+ T Follicular Helper Cells (Abstract 1739)
• Late Breaker: Distinct Contribution of Skin Dendritic Cell Subsets to the Efficacy of Epicutaneous Immunotherapy in Murine Models of Food Allergy (Abstract 1747)

Poster Presentations:

• Evaluation of Psychometric Parameters of Food Allergy Quality-of-Life Questionnaires With Item Response Theory for the Assessment of Health-Related Quality of Life during Food Allergy Treatments (Abstract 1247)
• Late Breaker: Quality of Life of Children and Adolescents With Food Allergy: Mapping FAQLQ-PF onto Paediatric-Specific Health State Utility Scores (Abstract 1719)
• Safety Benefits of an Increased Threshold in Milk-Allergic Patients: A Quantitative Risk Assessment Study (Abstract 1192)